$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-K Financial Statement

#000119312513103307 Filed on March 12, 2013

Income Statement

Concept	2013 Q1	2012	2011 Q4
Revenue	$2.750M	$0.00	$0.00
YoY Change	0.0%
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$2.357M	$0.00
YoY Change	0.0%
Gross Profit Margin	85.71%
Selling, General & Admin	$1.530M	$6.590M	$1.500M
YoY Change	-12.57%	-23.73%	-23.08%
% of Gross Profit	64.91%
Research & Development	$5.081M	$14.61M	$2.090M
YoY Change	90.73%	279.49%	19.43%
% of Gross Profit	215.57%
Depreciation & Amortization	$2.000K	$49.00K	$30.00K
YoY Change	-95.24%	-69.94%	-25.0%
% of Gross Profit	0.08%
Operating Expenses	$6.611M	$21.20M	$3.590M
YoY Change	49.91%	69.78%	-2.97%
Operating Profit	-$6.611M	-$21.20M
YoY Change	222.02%	69.78%
Interest Expense	-$5.000M	-$30.00K	$0.00
YoY Change	-72.66%	200.0%
% of Operating Profit
Other Income/Expense, Net	-$12.06M	-$13.18M	$7.360M
YoY Change	-36.98%	-245.15%	293.58%
Pretax Income	-$12.06M	-$34.38M	$3.770M
YoY Change	-48.79%	909.01%	-306.01%
Income Tax	-$2.762M	-$1.052M	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$16.49M	-$34.97M	$1.590M
YoY Change	56.52%	204.48%	-186.89%
Net Earnings / Revenue	-599.75%
Basic Earnings Per Share	-$1.84
Diluted Earnings Per Share	-$3.359B	-$16.00B	$2.556B
COMMON SHARES
Basic Shares Outstanding	83.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2012	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.19M	$35.49M	$11.40M
YoY Change	212.53%	210.5%	65.22%
Cash & Equivalents	$17.48M	$32.81M	$47.79M
Short-Term Investments	$9.709M	$2.680M
Other Short-Term Assets	$300.0K	$640.0K	$400.0K
YoY Change	-25.0%	68.42%	100.0%
Inventory		$0.00
Prepaid Expenses
Receivables		$0.00
Other Receivables		$0.00
Total Short-Term Assets	$27.50M	$36.12M	$11.81M
YoY Change	202.22%	205.84%	68.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.00K	$30.00K	$393.0K
YoY Change	-93.25%	-92.31%	-1.75%
Goodwill	$5.898M		$5.898M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$70.00K	$0.00
YoY Change
Total Long-Term Assets	$33.95M	$18.87M	$19.16M
YoY Change	77.74%	-1.51%	3731.6%
TOTAL ASSETS
Total Short-Term Assets	$27.50M	$36.12M	$11.81M
Total Long-Term Assets	$33.95M	$18.87M	$19.16M
Total Assets	$61.45M	$54.99M	$30.97M
YoY Change	117.91%	77.56%	312.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.123M	$1.980M	$2.155M
YoY Change	-18.35%	-8.33%	207.86%
Accrued Expenses	$7.478M	$2.040M	$2.168M
YoY Change	113.66%	-5.99%	97.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$500.0K
YoY Change		-100.0%
Long-Term Debt Due	$0.00	$10.00K	$0.00
YoY Change		-75.0%	-100.0%
Total Short-Term Liabilities	$26.38M	$15.92M	$11.20M
YoY Change	-3.73%	42.14%	124.04%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$50.00K	$0.00
YoY Change	-90.0%	66.67%
Other Long-Term Liabilities	$6.700M	$6.210M	$4.600M
YoY Change	26.42%	35.89%
Total Long-Term Liabilities	$6.800M	$6.260M	$4.600M
YoY Change	7.94%	36.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.38M	$15.92M	$11.20M
Total Long-Term Liabilities	$6.800M	$6.260M	$4.600M
Total Liabilities	$38.14M	$27.23M	$20.86M
YoY Change	-1.7%	30.54%	317.12%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$132.8M		$81.19M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M		$3.849M
YoY Change
Treasury Stock Shares	675.0K shares		675.0K shares
Shareholders Equity	$23.31M	$27.76M	$10.11M
YoY Change
Total Liabilities & Shareholders Equity	$61.45M	$54.99M	$30.97M
YoY Change	117.91%	77.56%	312.91%

Cashflow Statement

Concept	2013 Q1	2012	2011 Q4
OPERATING ACTIVITIES
Net Income	-$16.49M	-$34.97M	$1.590M
YoY Change	56.52%	204.48%	-186.89%
Depreciation, Depletion And Amortization	$2.000K	$49.00K	$30.00K
YoY Change	-95.24%	-69.94%	-25.0%
Cash From Operating Activities	-$5.331M	-$20.97M	-$4.170M
YoY Change	9.13%	42.98%	122.99%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions	$10.00M
YoY Change
Other Investing Activities	$0.00	-$90.00K	-$100.0K
YoY Change		-228.57%	-101.67%
Cash From Investing Activities	-$10.09M	-$87.00K	-$110.0K
YoY Change		-721.43%	-101.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$36.38M
YoY Change	-100.0%	95.42%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$92.00K	$42.43M	10.00K
YoY Change	-95.73%	121.06%	-133.33%
NET CHANGE
Cash From Operating Activities	-$5.331M	-$20.97M	-4.170M
Cash From Investing Activities	-$10.09M	-$87.00K	-110.0K
Cash From Financing Activities	$92.00K	$42.43M	10.00K
Net Change In Cash	-$15.33M	$21.37M	-4.270M
YoY Change	460.98%	370.59%	-205.43%
FREE CASH FLOW
Cash From Operating Activities	-$5.331M	-$20.97M	-$4.170M
Capital Expenditures			$0.00
Free Cash Flow	-$5.331M	-$20.97M	-$4.170M
YoY Change	9.13%	42.47%	127.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q2	us-gaap	Business Acquisition Contingent Consideration Potential Cash Payment BusinessAcquisitionContingentConsiderationPotentialCashPayment	32000000
CY2011Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.28
CY2012Q1	gale	Payment To Former Shareholders In Cash At Interest Factor PaymentToFormerShareholdersInCashAtInterestFactor	0.10	pure
CY2012Q2	us-gaap	Disposal Group Including Discontinued Operation Other Current Assets DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets	66000
CY2012Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1607000
CY2012Q2	us-gaap	Disposal Group Including Discontinued Operation Other Liabilities DisposalGroupIncludingDiscontinuedOperationOtherLiabilities	20000
CY2012Q2	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Net DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet	315000
CY2012Q2	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	87000
CY2012Q2	gale	Proceeds Under Breach Of Contract ProceedsUnderBreachOfContract	300000
CY2012Q2	gale	Disposal Group Including Discontinued Operation Convertible Notes DisposalGroupIncludingDiscontinuedOperationConvertibleNotes	1000000
CY2012Q2	gale	Disposal Group Including Discontinued Operation Liabilities DisposalGroupIncludingDiscontinuedOperationLiabilities	2159000
CY2012Q2	gale	Convertible Debt Rate Effective Percentage ConvertibleDebtRateEffectivePercentage	0.07	pure
CY2012Q2	gale	Convertible Share Conversion Price One ConvertibleShareConversionPriceOne	1000
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83067652	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36482000
CY2011Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	520000
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	868000
CY2011Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14121000	shares
CY2011Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2011Q3	gale	Adjustments To Additional Paid In Capital Liability Exercise For Warrant AdjustmentsToAdditionalPaidInCapitalLiabilityExerciseForWarrant	1036000
CY2012Q2	dei	Entity Public Float EntityPublicFloat	111370000
CY2011Q3	gale	Cash Contribution In Capital CashContributionInCapital	1500000
CY2011Q3	gale	Issue Of Series Preferred Stock IssueOfSeriesPreferredStock	9500000
CY2011Q3	gale	Percentage Of As Converted Common Stock PercentageOfAsConvertedCommonStock	0.83	pure
CY2011Q3	gale	Percentage Of Common Stock Shares Outstanding PercentageOfCommonStockSharesOutstanding	0.09999	pure
CY2010Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2251000	shares
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6891000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.10
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4333136	shares
CY2010Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure
CY2010Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	3138000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.40
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11202000
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	276000
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	816000
CY2011Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Assets DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets	783000
CY2011Q4	us-gaap	Assets Assets	30968000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11433000
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.03
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6163137	shares
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2011Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Current BusinessAcquisitionContingentConsiderationAtFairValueCurrent	1782000
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	101000
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18786000
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30968000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47811453	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36482000
CY2011Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	500000
CY2011Q4	us-gaap	Goodwill Goodwill	5898000
CY2011Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1747000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4673768	shares
CY2011Q4	us-gaap	Business Acquisition Purchase Price Allocation Assets Acquired Liabilities Assumed Net BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet	12827000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6885000
CY2011Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	193000
CY2011Q4	us-gaap	Liabilities Liabilities	20856000
CY2011Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	3000
CY2011Q4	us-gaap	Disposal Group Including Discontinued Operation Other Liabilities DisposalGroupIncludingDiscontinuedOperationOtherLiabilities	34000
CY2011Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Net DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet	355000
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000
CY2011Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	35000
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2168000
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	393000
CY2011Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	556000
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	5053000
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47136453	shares
CY2011Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	6351000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3160000
CY2011Q4	us-gaap	Assets Current AssetsCurrent	11810000
CY2011Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value BusinessAcquisitionContingentConsiderationAtFairValue	6351000
CY2011Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5053000
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	25000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	657000
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	81184000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1900000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	10112000
CY2011Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2011Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	32000
CY2011Q4	us-gaap	Ground Leases Accumulated Amortization GroundLeasesAccumulatedAmortization	95000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2155000
CY2011Q4	gale	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	755000
CY2011Q4	gale	Disposal Group Including Discontinued Operation Convertible Notes DisposalGroupIncludingDiscontinuedOperationConvertibleNotes	500000
CY2011Q4	gale	Disposal Group Including Discontinued Operation Liabilities DisposalGroupIncludingDiscontinuedOperationLiabilities	587000
CY2011Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	67228000
CY2011Q4	gale	Current Contingent Purchase Price Consideration CurrentContingentPurchasePriceConsideration	1782000
CY2011Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	4569000
CY2011Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000
CY2011Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	3746000
CY2011Q4	gale	Fair Value Of Contingent Purchase Price Consideration FairValueOfContingentPurchasePriceConsideration	6460000
CY2011Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	3746000
CY2011Q4	gale	Deferred Tax Assets Licensing Deduction Deferral DeferredTaxAssetsLicensingDeductionDeferral	7458000
CY2011Q4	gale	Fair Value Of Warrant Issued FairValueOfWarrantIssued	12809000
CY2012Q1	gale	Increase In Number Of Milestone Shares If Shareholders Approval Is Obtained IncreaseInNumberOfMilestoneSharesIfShareholdersApprovalIsObtained	0.76
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2288000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.01
CY2012Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	250000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41591000
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	116000
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	217000
CY2012Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	867000
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13216000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1626000
CY2012Q4	us-gaap	Marketable Securities MarketableSecurities	2678000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15919000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	535000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Equipment BusinessAcquisitionPurchasePriceAllocationEquipment	11000
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	32431000
CY2012Q4	us-gaap	Assets Assets	54986000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32807000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.54
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Current Liabilities Accounts Payable BusinessAcquisitionPurchasePriceAllocationCurrentLiabilitiesAccountsPayable	931000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7672384	shares
CY2012Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	6865000
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Current BusinessAcquisitionContingentConsiderationAtFairValueCurrent	935000
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	101000
CY2012Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	653000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23632000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54986000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83595837	shares
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	50500000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Notes Payable And Long Term Debt BusinessAcquisitionPurchasePriceAllocationNotesPayableAndLongTermDebt	1000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2012Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	1769000
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	41591000
CY2012Q4	us-gaap	Goodwill Goodwill	5898000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Current Assets Prepaid Expense And Other Assets BusinessAcquisitionPurchasePriceAllocationCurrentAssetsPrepaidExpenseAndOtherAssets	14000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Deferred Tax Liabilities Noncurrent BusinessAcquisitionPurchasePriceAllocationDeferredTaxLiabilitiesNoncurrent	5053000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5734817	shares
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Current Liabilities Accrued Liabilities BusinessAcquisitionPurchasePriceAllocationCurrentLiabilitiesAccruedLiabilities	143000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Assets Acquired Liabilities Assumed Net BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet	12827000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7944000
CY2012Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	-328000
CY2012Q4	us-gaap	Liabilities Liabilities	27230000
CY2012Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	74000
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2038000
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	5053000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82920837	shares
CY2012Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	7142000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3201000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	36121000
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value BusinessAcquisitionContingentConsiderationAtFairValue	7142000
CY2012Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5053000
CY2012Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	452000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	57200000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19000
CY2012Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	1052000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Current Assets Cash And Cash Equivalents BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents	168000
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	132168000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2000000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	27756000
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1394000
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	51000
CY2012Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Amount BusinessAcquisitionPurchasePriceAllocationGoodwillAmount	5898000
CY2012Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	350000
CY2012Q4	us-gaap	Ground Leases Accumulated Amortization GroundLeasesAccumulatedAmortization	11400
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1976000
CY2012Q4	gale	Business Acquisition Purchase Price Allocation In Process Research And Development BusinessAcquisitionPurchasePriceAllocationInProcessResearchAndDevelopment	12864000
CY2012Q4	gale	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1705000
CY2012Q4	gale	Estimated Value Of Earn Out EstimatedValueOfEarnOut	6460000
CY2012Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	102197000
CY2012Q4	gale	Current Contingent Purchase Price Consideration CurrentContingentPurchasePriceConsideration	935000
CY2012Q4	gale	Contractual Obligations Current Due ContractualObligationsCurrentDue	10956000
CY2012Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6207000
CY2012Q3	gale	Cash Paid For Interest On Final Milestone CashPaidForInterestOnFinalMilestone	35016
CY2012Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	1315849	shares
CY2012Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability	1000000
CY2006	gale	Reimbursement Of Expenses ReimbursementOfExpenses	363000
CY2012Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000
CY2012Q4	gale	Fair Value Of Shares Issued At Closing Including Escrowed Shares Expected To Be Released FairValueOfSharesIssuedAtClosingIncludingEscrowedSharesExpectedToBeReleased	6367000
CY2012Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	10964000
CY2012Q4	gale	Fair Value Of Contingent Purchase Price Consideration FairValueOfContingentPurchasePriceConsideration	6460000
CY2012Q4	gale	Number Of Unit Under Agreements For Sale And Issuance To Certain Investors NumberOfUnitUnderAgreementsForSaleAndIssuanceToCertainInvestors	3498256	shares
CY2012Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	10964000
CY2012Q4	gale	Deferred Tax Assets Licensing Deduction Deferral DeferredTaxAssetsLicensingDeductionDeferral	8194000
CY2012Q4	gale	Fair Value Of Warrant Issued FairValueOfWarrantIssued	7286000
CY2011Q1	gale	Executive Severance Agreements ExecutiveSeveranceAgreements	300000
CY2011Q2	us-gaap	Business Acquisition Effective Date Of Acquisition1 BusinessAcquisitionEffectiveDateOfAcquisition1	2011-04-13
CY2011Q2	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	5000000	shares
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9086000
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M13D
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	163000
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3322500	shares
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3851000
CY2011	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	80000
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-8078000
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M22D
CY2011	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.12
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3407000
CY2011	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value Low BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow	109000
CY2011	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.09
CY2011	us-gaap	Income Loss From Operations Before Extraordinary Items Per Basic And Diluted Share IncomeLossFromOperationsBeforeExtraordinaryItemsPerBasicAndDilutedShare	-0.32
CY2011	us-gaap	Interest Paid InterestPaid	6000
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36334413	shares
CY2011	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3407000
CY2011	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	7000
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	3001000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.21
CY2011	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	2000
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4542000
CY2011	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	172000
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2011	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	6367000
CY2011	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-4700000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.99
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11485000
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	84000
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit
CY2011	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	272000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-11485000
CY2011	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9079000
CY2011	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	260000
CY2011	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	54000
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8635000
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19196000
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8551000
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-99000
CY2011	us-gaap	Operating Expenses OperatingExpenses	12486000
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2011	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	101000
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.22
CY2011	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	65000
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53000
CY2011	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	73000
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1492499	shares
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3001000
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20283779	shares
CY2011	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2154000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.89
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1197000
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	500000
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18615000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3905000
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit
CY2011	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3712000
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14668000
CY2011	gale	Aggregate Intrinsic Value Of Stock Options Exercisable AggregateIntrinsicValueOfStockOptionsExercisable	0
CY2011	gale	Class Of Warrants Of Rights Issued ClassOfWarrantsOfRightsIssued	17950000	Warrant
CY2011	gale	Stock Based Compensation Expense StockBasedCompensationExpense	35000
CY2011	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	8986000
CY2011	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	6249000
CY2011	gale	Interest Income InterestIncome	-7000
CY2011	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	209000
CY2011	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	-70000
CY2011	gale	Value Of Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses	427000
CY2011	gale	Cash Received In Acquisition CashReceivedInAcquisition	168000
CY2011	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	95000
CY2011	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-8981000
CY2011	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-109000
CY2011	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	109000
CY2011	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	15000
CY2011	gale	Business Acquisitions Proforma Net Income Loss From Discontinued Operation BusinessAcquisitionsProformaNetIncomeLossFromDiscontinuedOperation	-8078000
CY2011	gale	Cash Excluding From Net Assets Acquired CashExcludingFromNetAssetsAcquired	168000
CY2011	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	-9000
CY2011	gale	Net Income Loss Including Other NetIncomeLossIncludingOther	11485000
CY2011	gale	Operating Lease Expense OperatingLeaseExpense	233000
CY2011	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	150000
CY2011	gale	Net Proceeds From Issuance Of Convertible Notes Payable NetProceedsFromIssuanceOfConvertibleNotesPayable	500000
CY2011	gale	Issuance Of Common Stock In Exchange Of Outstanding Warrants IssuanceOfCommonStockInExchangeOfOutstandingWarrants	3120000
CY2011	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	2205000
CY2011	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	12709000
CY2011	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	108000
CY2011	gale	Fair Value Of Common Stock Issued In Exchange For General And Administrative Expenses FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses	181000
CY2011	gale	Business Acquisition Proforma Earnings Per Share Basic From Discontinued Operation BusinessAcquisitionProformaEarningsPerShareBasicFromDiscontinuedOperation	-0.21
CY2011	gale	Stock Based Compensation Nonemployees StockBasedCompensationNonemployees	111000
CY2011	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	150000	shares
CY2011	gale	Income Tax Reconciliation Gain On Change In Fair Value Of Warrant Liability IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability	-3361000
CY2011	gale	Fair Value Of Contingent Consideration In Relation To Acquisition FairValueOfContingentConsiderationInRelationToAcquisition	6460000
CY2011	gale	Class Of Warrant Or Right Issued Exchanged For Other Warrant ClassOfWarrantOrRightIssuedExchangedForOtherWarrant		shares
CY2011	gale	Class Of Warrant Or Right Issued Exchanged For Common Stock ClassOfWarrantOrRightIssuedExchangedForCommonStock	5930000	shares
CY2011	gale	Fair Value Of Warrant Exchanged FairValueOfWarrantExchanged	3120000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1086000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	8766000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	713000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	631000
	us-gaap	Stock Issued1 StockIssued1	978000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-840000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25791000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	277000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-40712000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-72578000
	us-gaap	Interest Paid InterestPaid	12000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-71526000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	19000
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-207000
	us-gaap	Share Based Compensation ShareBasedCompensation	20252000
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	727000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	32807000
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	6367000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-110612000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	37497000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	220000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	35000
	us-gaap	Net Income Loss NetIncomeLoss	-112238000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-497000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3489000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46290000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	113388000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-645000
	us-gaap	Operating Expenses OperatingExpenses	72081000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1052000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1626000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	101000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	739000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	718000
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1052000
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2678000
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	266000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	37532000
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	50000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3335000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1865000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	101360000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	-1000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	19010000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-79741000
	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	32765000
	gale	Noncash Rent Expense NoncashRentExpense	29000
	gale	Interest Income InterestIncome	589000
	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	512000
	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	6269000
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	10843000
	gale	Value Of Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses ValueOfRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses	634000
	gale	Cash Received In Acquisition CashReceivedInAcquisition	168000
	gale	Cash Refunded Paid For Lease Deposit CashRefundedPaidForLeaseDeposit	-45000
	gale	Cash Transferred With Spin Off Transaction CashTransferredWithSpinOffTransaction	87000
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-1397000
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	2261000
	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	108000
	gale	Cash Excluding From Net Assets Acquired CashExcludingFromNetAssetsAcquired	168000
	gale	Allocation Of Management Expenses AllocationOfManagementExpenses	551000
	gale	Equipment And Furnishings Exchanged For Common Stock EquipmentAndFurnishingsExchangedForCommonStock	48000
	gale	Net Income Loss Including Other NetIncomeLossIncludingOther	112238000
	gale	Net Liabilities Distributed To Common Stock Holders In Rxi Spin Off Net Of Cash Transferred In Spin Off NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOffNetOfCashTransferredInSpinOff	2246000
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	5858000
	gale	Net Proceeds From Issuance Of Convertible Notes Payable NetProceedsFromIssuanceOfConvertibleNotesPayable	1000000
	gale	Issuance Of Common Stock In Exchange Of Outstanding Warrants IssuanceOfCommonStockInExchangeOfOutstandingWarrants	3120000
	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone	1579000
	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	10069000
	gale	Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrant FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrant	785000
	gale	Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants	785000
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	25324000
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	2402000
	gale	Fair Value Of Common Stock Issued In Exchange For General And Administrative Expenses FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses	3456000
	gale	Fair Value Of Common Stock Issued In Exchange For Licensing Rights FairValueOfCommonStockIssuedInExchangeForLicensingRights	3954000
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	dei	Trading Symbol TradingSymbol	GALE
CY2012	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13145000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y4M17D
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1800000	shares
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25937	shares
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-158000
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	49000
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Concentrations of Credit Risk</i> — Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of December 31, 2012, the company’s cash equivalents were invested in money market mutual funds. The company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. All of the non-interest bearing cash balances were fully insured at December 31, 2012 due to temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning in 2013, insurance coverage reverted to $250,000 per depositor at each financial institution, and the non-interest bearing cash balances may again exceed federally insured limits. As of December 31, 2012, we had approximately $32,431,000 in interest bearing accounts above federally insured limits.</font></p>
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21000
CY2012	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Reclassifications</i> — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></p>
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87000
CY2012	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	190978	shares
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.85
CY2012	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2869000
CY2012	us-gaap	Interest Paid InterestPaid	1000
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1644000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M13D
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-34377000
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.53
CY2012	us-gaap	Income Loss From Operations Before Extraordinary Items Per Basic And Diluted Share IncomeLossFromOperationsBeforeExtraordinaryItemsPerBasicAndDilutedShare	-0.56
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14614000
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62480666	shares
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-33325000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1394000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.99
CY2012	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	21374000
CY2012	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Derivative Financial Instruments</i> — During the normal course of business, from time to time, the company issues warrants and options to vendors as consideration to perform services. It may also issue warrants as part of a debt or equity financing. The company does not enter into any derivative contracts for speculative purposes.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The company recognizes all derivatives as assets or liabilities measured at fair value with changes in fair value of derivatives reflected as current period income or loss unless the derivatives qualify for hedge accounting and are accounted for as such. In accordance with FASB ASC Topic 815-40, “ <i>Derivatives and Hedging — Contracts in Entity’s Own Stock,”</i> the value of these warrants is required to be recorded as a liability, as the holders have an option to put the warrants back to the company upon the occurrence of certain events set forth in the warrant agreement.</font></p> </div>
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	152000
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.52
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-33343000
CY2012	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Nature of Business</b></font></td> </tr> </table> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Galena Biopharma, Inc. (“we,” “us,” “our,” “Galena” or the “company”) is a biopharmaceutical company focused on developing innovative, targeted oncology treatments to address major unmet medical needs to advance cancer care. We currently are developing innovative, peptide antigen-based “off the shelf” cancer immunotherapies for potential application to treatment of large populations of cancer survivors.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">We acquired NeuVax™ in April 2011 in connection with our merger acquisition of Apthera, Inc, or “Apthera” (see Note 4). Prior to that time, we were engaged primarily in conducting discovery research and preclinical development activities based on RNAi. In connection with our acquisition of NeuVax™, we reduced the scope of our RNAi activities.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">On September 26, 2011, we changed our name to Galena Biopharma, Inc. from RXi Pharmaceuticals Corporation in connection with the proposed partial spin-off of our former subsidiary, RXi Pharmaceuticals Corporation, or “RXi.” RXi was initially incorporated as RNCS, Inc. and assumed the name RXi Pharmaceuticals Corporation in conjunction with the change in our name to Galena. On April 26, 2012, we completed the partial spin-off of RXi, which is engaged in the development of novel RNAi-based therapies.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Unless the context otherwise indicates, references in this annual report to the “company,” “we,” “us” or “our” refer (i) to Galena, Apthera and RXi, collectively, prior to the partial spin-off of RXi; and (ii) to only Galena and Apthera, together, after the partial spin-off.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">As the company has not generated any revenue from inception through December 31, 2012, the company is considered a development-stage company for accounting purposes.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The company had cash and cash equivalents of approximately $32.8 million as of December 31, 2012. The company believes that its existing cash and cash equivalents should be sufficient to fund its operations through at least the second quarter of 2014. This projection is based on our current planned operations and is subject to changes in our plans and uncertainties inherent in our business, and we may need to seek to replenish our existing cash and cash equivalents sooner than we project.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">  </p> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">We have not generated revenue to date and may not generate product revenue in the foreseeable future, if ever. We expect to incur significant operating losses as we advance our product candidates through the drug development and regulatory process. We expect to continue to devote a substantial portion of our resources to research and development programs. As a result of the costs expected to be incurred in connection with our recently commenced clinical trials of NeuVax and FBP, our research and development expense has increased significantly from historic levels. We will need to generate significant revenue to achieve profitability and might never do so. In the absence of product revenue, our potential sources of operational funding are expected to be the proceeds from equity financings, funded research and development payments and payments received under partnership and collaborative agreements. There is no guarantee that additional funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations, or to seek to merge with or to be acquired by another company.</font></p> </div>
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	10000
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1052000
CY2012	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	40500
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-34969000
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13178000
CY2012	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	8700
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6585000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42424000
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8939000
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit
CY2012	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	2370000
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-396000
CY2012	us-gaap	Operating Expenses OperatingExpenses	21199000
CY2012	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3273292	shares
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1052000
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1626000
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.03
CY2012	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	6160
CY2012	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	364000
CY2012	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1052000
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit
CY2012	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2678000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	264816	shares
CY2012	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	266000
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1394000
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20887960	shares
CY2012	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	5.19
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Uses of estimates in preparation of financial statements</i> — The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</font></p>
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-139000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.70
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1067000
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	641000
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	36378000
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1052000
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11688000
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-894000
CY2012	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14034000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20963000
CY2012	gale	Expense Recognized For Change In Fair Value ExpenseRecognizedForChangeInFairValue	579000
CY2012	gale	Class Of Warrants Of Rights Issued ClassOfWarrantsOfRightsIssued	7978000	Warrant
CY2012	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	3.4	Y
CY2012	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	1240026
CY2012	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-10775000
CY2012	gale	General And Administrative Expenses GeneralAndAdministrativeExpenses	5406000
CY2012	gale	Cash Excluding From Net Assets Acquired CashExcludingFromNetAssetsAcquired	168000
CY2012	gale	Aggregate Intrinsic Value Of Stock Options Exercisable AggregateIntrinsicValueOfStockOptionsExercisable	17650
CY2012	gale	Maximum Percentage Of Deferred Tax Asset To Establishes Valuation Allowance MaximumPercentageOfDeferredTaxAssetToEstablishesValuationAllowance	1.00	pure
CY2012	gale	Interest Income InterestIncome	-33000
CY2012	gale	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	17000000
CY2012	gale	Proceeds From Technology Revenue ProceedsFromTechnologyRevenue	45000000
CY2012	gale	Proceeds From Technology Revenue Under Condition One ProceedsFromTechnologyRevenueUnderConditionOne	15000000
CY2012	gale	Proceeds From Technology Revenue Under Condition Two ProceedsFromTechnologyRevenueUnderConditionTwo	30000000
CY2012	gale	Research And Development Employee Stock Based Compensation Expense ResearchAndDevelopmentEmployeeStockBasedCompensationExpense	303000
CY2012	gale	Research And Development Non Employee Stock Based Compensation Expense ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense	277000
CY2012	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	10843000
CY2012	gale	Cash Transferred With Spin Off Transaction CashTransferredWithSpinOffTransaction	87000
CY2012	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	10775000
CY2012	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	2370000
CY2012	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-2370000
CY2012	gale	Common Stock Issued In Connection With Espp CommonStockIssuedInConnectionWithEspp	93000
CY2012	gale	Net Income Loss Including Other NetIncomeLossIncludingOther	34969000
CY2012	gale	Operating Lease Expense OperatingLeaseExpense	139000
CY2012	gale	Net Liabilities Distributed To Common Stock Holders In Rxi Spin Off Net Of Cash Transferred In Spin Off NetLiabilitiesDistributedToCommonStockHoldersInRxiSpinOffNetOfCashTransferredInSpinOff	2246000
CY2012	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	5708000
CY2012	gale	Net Proceeds From Issuance Of Convertible Notes Payable NetProceedsFromIssuanceOfConvertibleNotesPayable	500000
CY2012	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone	1579000
CY2012	gale	General And Administrative Employee Stock Based Compensation GeneralAndAdministrativeEmployeeStockBasedCompensation	479000
CY2012	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	7286000
CY2012	gale	Fair Value Of Common Stock Issued In Exchange For General And Administrative Expenses FairValueOfCommonStockIssuedInExchangeForGeneralAndAdministrativeExpenses	700000
CY2012	gale	Minimum Likely Hood For More Likely Than Not Threshold MinimumLikelyHoodForMoreLikelyThanNotThreshold	0.50	pure
CY2012	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15	pure
CY2012	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08	pure
CY2012	gale	Stock Based Compensation Nonemployees StockBasedCompensationNonemployees	977000
CY2012	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	8883000	shares
CY2012	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	10843000
CY2012	gale	Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents	P90D
CY2012	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Term Post Resignation Under Condition One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableTermPostResignationUnderConditionOne	P2Y
CY2012	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Term Post Term Of Scientific Advisory Board Agreement Under Condition Two ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableTermPostTermOfScientificAdvisoryBoardAgreementUnderConditionTwo	P90D
CY2012	gale	Income Tax Reconciliation Gain On Change In Fair Value Of Warrant Liability IncomeTaxReconciliationGainOnChangeInFairValueOfWarrantLiability	3664000
CY2012	gale	Income Tax Reconciliation Unrealized Gain On Marketable Securities IncomeTaxReconciliationUnrealizedGainOnMarketableSecurities	-1052000

Files In Submission

Name	View Source	Status
0001193125-13-103307-index-headers.html	Edgar Link	pending
0001193125-13-103307-index.html	Edgar Link	pending
0001193125-13-103307.txt	Edgar Link	pending
0001193125-13-103307-xbrl.zip	Edgar Link	pending
d459781d10k.htm	Edgar Link	pending
d459781dex1018.htm	Edgar Link	pending
d459781dex1039.htm	Edgar Link	pending
d459781dex1040.htm	Edgar Link	pending
d459781dex1043.htm	Edgar Link	pending
d459781dex106.htm	Edgar Link	pending
d459781dex231.htm	Edgar Link	pending
d459781dex311.htm	Edgar Link	pending
d459781dex312.htm	Edgar Link	pending
d459781dex321.htm	Edgar Link	pending
d459781dex41.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g4597812.jpg	Edgar Link	pending
g4597813.jpg	Edgar Link	pending
g459781figure-1.jpg	Edgar Link	pending
g459781figure-2.jpg	Edgar Link	pending
g459781neu-vax.jpg	Edgar Link	pending
g459781our-oncology1.jpg	Edgar Link	pending
g459781our-oncology2.jpg	Edgar Link	pending
gale-20121231.xml	Edgar Link	completed
gale-20121231.xsd	Edgar Link	pending
gale-20121231_cal.xml	Edgar Link	unprocessable
gale-20121231_def.xml	Edgar Link	unprocessable
gale-20121231_lab.xml	Edgar Link	unprocessable
gale-20121231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2013 Q1 Form 10-K Financial Statement

#000119312513103307 Filed on March 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2013 Q1 Form 10-K Financial Statement

#000119312513103307 Filed on March 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls